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Type 2 Diabetes: When Insulin Minireview
Secretion Fails to Compensate
for Insulin Resistance
docking proteins called insulin receptor substrates (IRSs).
IRSs bind to various effector molecules including the
regulatory subunit of phosphoinositol 3-kinase via Src
homology 2 (SH2) domains. Recruitment of the catalytic
subunit results inactivation of phosphoinositol 3-kinase,
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Boston, Massachusetts 02215 which is necessary for insulin action on glucose trans-
port, glycogen synthase, protein synthesis, antilipolysis,
and suppression of hepatic gluconeogenesis by regu-
lation of phosphoenolpyruvate carboxykinase (PEPCK)Diabetes mellitus is the most common metabolic dis-
gene expression. Evidence suggests that the serine/ease worldwide. Every day, 1700 new cases of diabetes
threonine kinase, Akt/PKB, is one downstream mediatorarediagnosed in theUnited States, and at least one-third
of phosphoinositol 3-kinase and could play a role inof the 16 million Americans with diabetes are unaware of
insulin stimulation of glucose transport. Insulin receptorit. Diabetes is the leading cause of blindness, renal fail-
phosphorylation also activates the ras/MAP kinase cas-ure, and lower limb amputations in adults and is a major
cade, which is not necessary for insulin action on glu-risk factor for cardiovasculardisease and stroke. Normal
cose transport but plays an important role in mitogenicglucose homeostasis requires the finely tuned orches-
effects of insulin (Myers and White, 1996). Attempts totration of insulin secretion by pancreatic b cells in re-
identify mutations or polymorphisms in genes encodingsponse to subtle changes in blood glucose levels, deli-
insulin signaling molecules that account for the geneticcately balanced with secretion of counter-regulatory
predisposition to the common forms of Type 2 diabeteshormones such as glucagon. Type 1 diabetes results
has been generally unrevealing.However, recent studiesfrom autoimmune destructionof pancreatic b cells caus-
in transgenic mice (reviewed in Patti and Kahn, 1996)ing insulin deficiency. Type 2 or noninsulin-dependent
provide important insights.diabetes mellitus (NIDDM) accounts for .90% of cases
Diabetes in IRS-2 Knockout Miceand is characterized by a triad of (1) resistance to insulin
Last week, Withers et al., reported that disruption ofaction on glucose uptake in peripheral tissues, espe-
IRS-2 causes diabetes in mice. The most compellingcially skeletal muscle and adipocytes, (2) impaired insu-
aspect of this report is that inactivation of this singlelin action to inhibit hepatic glucose production, and (3)
gene causes defects in both insulin action and insulindysregulated insulin secretion (DeFronzo, 1997). In most
secretion. IRS-2 knockout mice have hyperglycemia ascases, Type 2 diabetes is a polygenic disease with com-
early as 3 days postbirth, and insulin levels are initiallyplex inheritance patterns (reviewed in Kahn et al., 1996;
increased, thehallmark of insulin resistance. These miceDeFronzo, 1997). Environmental factors, especially diet,
show progressive deterioration of glucose homeostasisphysical activity, and age, interact with genetic predis-
with severediabetes at 10±16 weeks of agedue to insulinposition to affect disease prevalence. Susceptibility to
resistance in liver and skeletal muscle and b cell failure.both insulin resistance and insulin secretory defects ap-
This is distinctly different from the consequences ofpears to be genetically determined (Kahn et al., 1996;
DeFronzo, 1997). Defects in insulin action precede the
overt disease and are seen in nondiabetic relatives of
diabetic subjects. Initially, increased insulin secretion
compensates for insulin resistance but overt disease
occurs over time as b cell compensation fails. The possi-
bility that Type 2 diabetes could result from primary
defects in the b cell in some cases is demonstrated by
rare subtypeswith mutations in genes encoding glucoki-
nase, or transcription factors such as hepatic nuclear
factors (HNF)-1a, -1b, and -4a, or IPF1, causing maturity
onset diabetes in the young (MODY). In spite of intense
investigation, the genes responsible for the common
forms of Type 2 diabetes remain unknown.
Insulin Signaling: The Basics
Insulin action on glucose uptake in muscle and fat re-
sults from a cascade of signaling events emanating from
the insulin receptor and culminating in translocation of
the major insulin responsive glucose transporter, GLUT4,
from intracellular vesicles to the plasma membrane (My-
Figure 1. Insulin Signaling Pathways
ers and White, 1996; Holman and Kasuga, 1997) (Figure
IRSs, insulin responsive substrates; PDKs, phosphoinositide-depen-1). Insulin binds to its cell surface transmembrane re-
dent protein kinases; GSK3, glycogen synthase kinase 3; Akt/PKB,
ceptor stimulating receptor autophosphorylation and protein kinase B; p110, catalytic subunit; p85, regulatory subunit of
activation of the intrinsic tyrosine kinase activity, which phosphoinositide 3-kinase. Dotted lines indicate effects that are still
under investigation.results in tyrosine phosphorylation of several cytosolic
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disruption of IRS-1 (Araki et al., 1994; Tamemoto et al., hypersecrete insulin. Only individuals in whom b cell
compensation is inadequate develop diabetes. The criti-1994), which causes growth retardation and mild insulin
cal partnership between genetic determinants of insulinresistance but not frank diabetes because insulin secre-
action and insulin secretion has previously been demon-tion increases to compensate for the resistance. Indeed,
strated in transgenic mice with simultaneous disruptionthe relatively mild insulin resistance and residual ability
of two separate genes, for example, IRS-1 impairingof insulin to partially stimulate glucose uptake in tissues
insulin action and glucokinase impairing insulin secre-of IRS-1 knockout mice (Araki et al., 1994; Tamemoto
tion (Terauchi et al., 1997). However, the current reportet al., 1994) were important clues to the existence of
gives substance to the speculation that defects in aother IRSs including IRS-2. In retrospect, differences in
single gene product could impair both insulin action andthe consequences of IRS-1 and IRS-2 disruption might
secretion, thereby causing diabetes.be expected since, in spite of high homology of these
Humans with Type 2 diabetes have reduced b cellproteins, recent data demonstrate unique interactions
mass compared to weight-matched nondiabetic sub-with activated insulin receptors and different tyrosine
jects (Kloppel et al., 1985), consistent with the animalphosphorylation motifs in the COOH termini suggest
data showing that failure of b cell compensation is asso-unique signaling patterns (see references in Bernal et
ciated with diabetes. Intense research has focused onal., 1998). Tissue distribution indicates that IRS-2 mRNA
promoting islet cell growth and/or survival in models ofis more abundant than IRS-1 in liver and pancreas (Ber-
Type 2 diabetes as well as in islet transplantation studiesnal et al., 1998), although both are widely expressed and
aimed at both Type 1 and 2 diabetes. Understanding theare abundant in muscle. In insulin-resistant states in
mechanisms by which IRS-2 can foster islet hyperplasiarodents and humans, IRS-1 and IRS-2 are differentially
could have implications for therapeutic approaches toregulated in different tissues and the relative importance
augment islet mass either in vivo or ex vivo in combina-of each IRS (including also IRS-3, IRS-4, Gab1, etc.) for
tion with islet transplantation. The parallels between thespecific actions of insulin in a given tissue is currently
IRS-2 knockout mice and Type 2 diabetes in humansunder investigation.
raises the tantalizing question as to whether human dia-Pancreatic b Cell Compensation Distinguishes
betes is caused by mutations in the IRS-2 gene. Disap-IRS-1 from IRS-2 Knockouts
pointingly, studies in press inseveral populations includ-The reduction in pancreatic b cell mass even in neonatal
ing Danish Caucasians (Bernal et al., 1998) reveal no
IRS-2 knockout mice and the inability to increase b cell
association between polymorphisms in the IRS-2 gene
mass in the face of insulin resistance are critical to the
and Type 2 diabetes.
development of diabetes. In contrast, the capacity for
Do All Paths Lead to the Same Syndrome?
b cell hyperplasia in IRS-1 knockout mice most likely
The Insulin Receptor. While complete absence of the
protects them against frank diabetes. In the early stages
insulin receptor results in severe metabolic abnormali-
of the development of diabetes in the IRS-2 knockout ties and neonatal death in humans and rodents, mice
mice, glucose-stimulated insulin release in vivo is nor- with 50% reduction of insulin receptors due to one null
mal. Subsequently, the impact of the failure of normal allele compensate by hypersecreting insulin, resulting
b cell expansion postweaning becomes manifest,hyper- in normal glucose tolerance (Accili, 1997). Overexpres-
glycemia progresses, and insulin release is attenuated. sion of normal insulin receptors in skeletal muscle, the
This sequence is reminiscent of Type 2 diabetes in hu- major site of insulin-mediated glucose uptake, has a
mans and may result, at least in part, from ªglucose relatively mild effect to increase insulin sensitivity and
toxicityº or glucose-induced desensitization, the phe- expression of a kinase-deficient receptor mutant results
nomenon by which increased metabolites of the hex- in only mild insulin resistance without diabetes (re-
osamine biosynthetic pathway abrogate glucose sens- viewed in Patti and Kahn, 1996). These data are consis-
ing/insulin secretion in b cells as well as insulin action tent with the ªspare receptorº concept reflecting the
in muscle and fat (McClain and Crook, 1996; DeFronzo, fact that activation of the full cohort of insulin receptors
1997). This propels a vicious cycle, further aggravating is not required for normal insulin action. In humans, a
hyperglycemia. The presence of IRS-2 in pancreatic number of mutations in the insulin receptor have been
ductal epithelium, the site of neogenesis of islets from described and the phenotypes range from mild glucose
ductal precursor cells, in normal mice and the reduced intolerance to severe diabetes (Kahn et al., 1996). Such
islet mass and failure to undergo hyperplasia in IRS-2 mutations constitute a very rare cause of Type 2 dia-
null mice (Withers et al., 1998) suggest potentially a betes.
more direct role for IRS-2-dependent signaling in the Glucose Transporters. Genetic manipulation of GLUT4,
regulation of islet cell replication, neogenesis and/or a more distal (Figure 1) but major mediator of insulin
apoptosis. action on glucose transport in muscle and fat, results
Implications for Human Diabetes in relatively dramatic phenotypes. Overexpression of
Diabetes in the IRS-2 knockout mouse providesa mono- GLUT4 in muscle and/or adipose tissue in transgenic
genic mechanism for the long-standing observation that mice results in fasting hypoglycemia, enhanced glucose
overt Type 2 diabetes occurs when insulin secretory tolerance, and increased insulin sensitivity (reviewed in
capacity can not adequately compensate for impair- Katz etal., 1996). GLUT4 overexpression hasa therapeu-
ments in insulin action (DeFronzo, 1997). In humans, this tic effect to improve glucose homeostasis and insulin
phenomenon is illustrated by the fact that obesity is a sensitivity in genetically obese, diabetic db/db mice or
major risk factor for Type 2 diabetes. Whereas obesity mice rendered insulin resistant by high fat feeding or
is invariably associated with insulin resistance, most frankly diabetic by injection of the b cell toxin streptozo-
tocin. In the db/db and high fat fed models, increasedobese people are not diabetic due to their capacity to
Minireview
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GLUT4 overcomes multiple defects in insulin signal- transgenic mice overexpressing normal insulin in the
liver. These mice are hyperinsulinemic and show an age-ing. Hence, if gene therapy were more feasible for hu-
mans, GLUT4 would be a promising target. Interestingly, related reduction in insulin receptor expression, glucose
intolerance, and hyperlipidemia without any primary de-the same phenotype is not seen with overexpression
of GLUT1, which results in fasting hypoglycemia but fects in insulin action or secretion (reviewed in Patti and
Kahn, 1996). Interestingly, in insulin-resistant, normogly-resistance to insulin stimulated glucose uptake. This
most likely results from constitutively high glucose flux cemic mice with one disrupted GLUT4 allele, insulin
action is impaired in muscle but not in liver. It will bethrough the hexosamine biosynthetic pathway (glucose
toxicity hypothesis). Thus, increasing glucose transport important to determine whether hepatic insulin resis-
tance develops as these mice become more severelyby any mechanism does not necessarily enhance insulin
sensitivity. hyperinsulinemic and hyperglycemic.
Importance of Genetic BackgroundMice that are heterozygous for a null allelle for GLUT4
are normal at birthbut males develop progressive hyper- Mice with combined heterozygous deficiencies in the
insulin receptor and IRS-1 genes were created to reca-insulinemia and .50% become overtly diabetic by 4±5
months (Stenbit et al., 1997). Thus, a relatively mild de- pitulate the polygenic natureof Type 2 diabetes (BruÈ ning
et al., 1997). While mice heterozygous for either defectfect can initiate a sequence of events that eventuates
in Type 2 diabetes in midlife, similar to the progres- alone have subclinical phenotypes, thedouble heterozy-
gotes are highly insulin-resistant and 40% develop Typesion in humans. Interestingly, homozygous disruption
of GLUT4 results in growth retardation, severe reduction 2 diabetes at 4±6 months of age despite massive hyper-
insulinemia and pancreatic b cell hyperplasia. The factin adipose tissue, cardiac hypertrophy and failure, but
not diabetes (Katz et al., 1996). Multiple alterations in that the highest insulin levels and greatest b cell hyper-
plasia occur amongthe mice that develop overt diabetesorgan function and fuel availability and metabolism are
evident, and delineation of the molecular physiology will indicates that in this model, even exuberant b cell com-
pensation for insulin resistance is inadequate in somebe possible with tissue-specific reconstitution as well
as tissue-specific GLUT4 knockout using theCre recom- mice. But what about the other 60% of mice that do not
develop diabetes despite the same genetic defects?binase loxP system, ideally with inducible promoters in
transgenic mice. Most likely the ªclinicalº impact of these defects is modi-
fied by other genetic factors, especially since thesep21ras. Overexpression of the low molecular weight GTP
binding protein, p21ras driven by an adipose-specific pro- knockout experiments are performed in outbred popula-
tions.moter/enhancer in transgenic mice results in reduced
adipose mass and increased insulin sensitivity (House- The importance of genetic background has clearly
been demonstrated by feeding different strains of miceknecht et al., 1996). Studies in isolated adipocytes from
transgenic mice indicate that this may be mediated by high fat diets. The strains respond with widely varying
degrees of hyperinsulinemia and only some developincreased translocation of GLUT4 to the cell surface.
However, other in vitro evidence indicates that blocking overt diabetes (Surwit et al., 1991). Backcrossing indi-
cates that insulin resistance in these mice is determinedras activation does not impair insulin action on glucose
transport (Holman and Kasuga, 1997). Importantly, this by a dominant gene whereas hyperglycemia (i.e., failure
of b cell compensation) is determined by a recessivetransgenic model illustrates that even when manipula-
tion of a signaling pathway mimics insulin's effects, one gene. Similarly, the severity of diabetes in mice with
mutations in genes encoding leptin (ob) or the leptincannot conclude that this pathway is critical for the
normal action of insulin onglucose homeostasis. Prelim- receptor (db) is significantly altered by genetic back-
ground. When ob or db is expressed on the C57BL/Ksinary data indicate that such models will provide impor-
tant insights into the cross-talk between signal trans- background, severe diabetes occurs in association with
b cell atrophy (Coleman, 1978). The same mutations onduction pathways.
PEPCK. Overexpression of PEPCK, the rate limiting en- the C57BL/6 background result in obesity and extreme
insulin resistance but only mild hyperglycemia becausezyme in gluconeogenesis, in transgenic mice targets
insulin action in liver (Valera et al., 1994). The conse- b cell hyperplasia and hypertrophy occur. Positional
cloning studies are aimed at determining the gene(s)quences are seen in all insulin target tissues and resem-
ble the constellation of defects in Type 2 diabetes. Mice responsible for differences in b cell neogenesis, hyper-
tropy, and/or apoptosis in these strains.overexpressing PEPCK have increased hepatic glucose
production and hepatic insulin resistance resulting in In humans, it is possible that defined genetic varia-
tions, for example in insulin signaling molecules, mayhyperglycemia and hyperinsulinemia. Secondarily, ex-
pression of the GLUT4 glucose transporter is down- be modified by constellations of other genes, account-
ing for the complex inheritance patterns of Type 2 diabe-regulated in skeletal muscle causing resistance to insu-
lin action on glucose uptake. Such models indicate that tes. For example, the IRS-1 gene is highly polymorphic
with coding sequence variations in z5% of normal peo-whether insulin resistance originates in liver, muscle, or
fat, eventually all insulin target tissues may be affected. ple and in 10%±20% of subjects with Type 2 diabetes
(Kahn et al., 1996). Furthermore, decreased levels ofThis may be mediated in part by the compensatory hy-
perinsulinemia itself that down-regulates insulin recep- both the insulin receptor and IRS-1 are seen in insulin
target tissues of humans and rodents with Type 2 diabe-tors and desensitizes postreceptor pathways (Patti and
Kahn, 1996), and by associated metabolic derange- tes. The impact of these polymorphisms or reduced
expression of signaling molecules could be modified byments such as elevated plasma free fatty acids (De-
Fronzo, 1997). This phenomenon has been confirmed in traits as genetically complicated as those that influence
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the level of or response to physical activity, thus modi- uncovering synergy between two subclinical defects,
testing the impact of superimposed metabolic and life-fying the genetic predisposition to diabetes. The insulin
receptor/IRS1 double null heterozygotes demonstrate style variations (e.g., diet, inactivity, stress), and devel-
oping new strategies for the prevention and treatmentthat a multiplex of geneticmutations maynot be required
and alterations in only two genes could be sufficient to of diabetes and its complications.
cause diabetes on certain genetic backgrounds. Back-
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Generation of signals orbiochemical molecules that pre-
dispose to diabetes may originate in the brain; a likely
example is insulin resistance in the db/db (leptin recep-
tor mutant) mouse. Efforts to identify diabetogenes are
now taking a broader focus extending to secretory prod-
ucts of adipocytes (leptin, TNF) and neuropeptides.
Thorough testing for concurrent mutations in several
candidate genes, albeit a major undertaking, could pay
off, expecially when paired with specific biochemical
or physiologic subphenotypes. Transgenic models in
which one or more candidate genes are manipulated
either singly or in combination will continue to be a
valuable approach to identifying new susceptibility loci,
